Stability and sterility of diluted enoxaparin under three different storage conditions

Journal of Paediatrics and Child Health

Volumn 47, Issue 5, 2011, Pages 299-301

  Summerhayes, Robyn ^a,b   Chan, Maria ^a,c   Ignjatovic, Vera ^a,b   Prankerd, Richard ^a   Monagle, Paul ^b,d  

^a ROYAL CHILDREN'S HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c Pharmacy Department   (Australia)

^d MONASH UNIVERSITY   (Australia)

Author keywords

anti factor Xa; enoxaparin; low molecular weight heparin; paediatric; stability

Indexed keywords

BLOOD CLOTTING FACTOR 10A; ENOXAPARIN; POLYPROPYLENE; PROTHROMBIN A; SODIUM CHLORIDE;

ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; DILUTION; DRUG STABILITY; DRUG STERILITY; DRUG STORAGE; FREEZING; LIGHT; PRIORITY JOURNAL; ROOM TEMPERATURE;

ANTICOAGULANTS; DRUG STABILITY; DRUG STORAGE; ENOXAPARIN; FACTOR XA; PEDIATRICS; TEMPERATURE;

EID: 79957595684     PISSN: 10344810     EISSN: 14401754     Source Type: Journal    
DOI: 10.1111/j.1440-1754.2010.01949.x     Document Type: Article

References (16)

1. Andrew M, David M, Adams M, et al,. Venous thromboembolic complications (VTE) in children: first analyses of the Canadian Registry of VTE. Blood 1994; 83: 1251-7. (Pubitemid 24062848)
2. Massicotte MP,. Low-molecular-weight heparin therapy in children. J. Pediatr. Hematol. Oncol. 2001; 23: 189-94. (Pubitemid 32332050)
3. Goldenberg NAJL, Hathaway H, Tripputi M, Primeaux J, Child J,. Anti-Xa stability of diluted dalteparin for pediatric use. Ann. Pharmacother. 2008; 42: 511-5. (Pubitemid 351521965)
4. Monagle P, Chalmers E, Chan A, et al,. Antithrombotic therapy in neonates and children: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 887-968.
5. Revel-Vilk S, Massicotte P,. Thromboembolic diseases of childhood [review]. Blood Rev. 2003; 17: 1-6. (Pubitemid 36176206)
6. Monagle P, Adams M, Mahoney M, et al,. Outcome of pediatric thromboembolic disease: a report from the Canadian Childhood Thrombophilia Registry. Pediatr. Res. 2000; 47: 763-6. (Pubitemid 30365435)
7. Raffini J, Huang Y, Witmer C, Feudtner C,. A significant increase in venous thromboembolism in hospitalized children in the United States from 2001 to 2007 [conference abstract]. Pediatrics 2009; 124: 1001-7.
8. Albisetti M, Andrew M,. Low molecular weight heparin in children. Eur. J. Paediatr. 2002; 161: 71-7. (Pubitemid 34143498)
9. Parasuraman S, Goldhaber SZ,. Venous thromboembolism in children [review]. Circulation 2006; 113: e12-6.
10. Dager WE, Gosselin RC, King JH, Christensen CL, Owings JT, Larkin EC,. Anti-Xa stability of diluted enoxaparin for use in pediatrics. Ann. Pharmacother. 2004; 38: 569-73. (Pubitemid 38352215)
11. Charland SL, Davis DD, Tillman DJ,. Activity of enoxaparin sodium in tuberculin syringes for 10 days. Am. J. Health Syst. Pharm. 1998; 55: 1296-8. (Pubitemid 28280776)
12. Hamilton MA, Stangb L, Etches WS, Rennie R, Mant MJ,. Stability of low molecular weight heparins stored in plastic syringes. Thromb. Res. 2003; 112: 117-9.
13. Mewborn AL, Kessler JM, Joyner K,. Compatibility and activity of enoxaparin sodium in 0.9% sodium chloride injection for 48 hours. Am. J. Health Syst. Pharm. 1996; 53: 167-9. (Pubitemid 26030909)
14. Patel RP, Narkowicz C, Jacobson GA,. In vitro stability of enoxaparin solutions (20 mg/mL) diluted in 4% glucose. Clin. Ther. 2008; 30: 1880-5.
15. Contant G, Gouault-Heilman M,. Automated amidolytic (Anti IIa) heparin assay. Thromb Haemost. 1983; 50: Abs# 0429.
16. Clexane Product Data Sheet. Sanofi-Aventis. 2008. Available from: [accessed May 2008].